Table II.

Hazard ratios and 95% confidence intervals for the association between marijuana use and all-cause mortality among 2,097 participants in the MI Onset Study followed for up to 18 years

Follow- Up	Marijuan a Use	# Deaths	Person -Years	Age/Sex Adjusted HR (95% CI) P-Value	Fully Adjusted* HR (95% CI) P-Value	P- trend†
0–18 years	None	497	24,452	1.00 (reference)	1.00 (reference)	0.32
	Any	22	1,333	1.28 (0.82–1.98) 0.28	1.29 (0.81–2.05) 0.28
	<1 per Week	13	706	1.36 (0.78–2.38) 0.28	1.31 (0.74–2.35) 0.36
	≥1 per Week	9	615	1.19 (0.61–2.33) 0.61	1.27 (0.63–2.56) 0.51
0–10 years	None	355	18,085	1.00 (reference)	1.00 (reference)	0.17
	Any	19	975	1.55 (0.96–2.49) 0.08	1.45 (0.88–2.40) 0.15
	<1 per Week	11	511	1.63 (0.89–3.00) 0.12	1.45 (0.77–2.73) 0.26
	≥1 per Week	8	454	1.46 (0.72–3.00) 0.30	1.47 (0.69–3.12) 0.32

^*Adjusted for age (continuous), sex, race (white versus other), body mass index (continuous and quadratic terms), marital status (married versus other), smoking status (never, former, current), usual frequency of physical activity (none, 1 to 4 episodes per week, 5 or more episodes per week), tea consumption (none, <2 cups per day, 2 or more cups per day), alcohol intake (tertiles), binge drinking (≥3 drinks in a 2-hour period within the last year, yes/no), any cocaine use in the previous year (yes/no), neighborhood median household income (tertiles), years of education (less than high school, high school graduate, some college), previous MI, congestive heart failure, diabetes mellitus, hypertension, noncardiac comorbidities (yes/no), current medication use (yes/no; aspirin, β-blockers, calcium-channel blockers, digoxin, diuretics, hypolipidemic agents, and angiotensin-converting enzyme inhibitors), thrombolytic therapy.

^†P-trend for no marijuana use, <1 per week and ≥1 per week in the fully adjusted model